newsfilter
← Latest News
GlobeNewswire·

Caladrius Biosciences Reports Second Quarter 2022 Financial Results and Provides Business Update

Merger with Cend Therapeutics remains on track to close in the third quarter of 2022, subject to stockholder approval, resulting in the formation of Lisata Therapeutics Conference call begins today at 4:30 p.m. Eastern time BASKING RIDGE, N.J., Aug